BioPharma Longitude Capital raises $525M for third fund spanning early to late stage medtech investments By Stephanie Baum
Devices & Diagnostics Life science investor Longitude Capital will use its $325M fund in later-stage deals By Chris Seper
Devices & Diagnostics Longitude Venture Partners goes after a $375M second fund for life science investments By
Pharma, Startups UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm By Alaric DeArment
Top Story Morning Read: Larry Ellison donates $200M to set up cancer research center at USC, Theranos COO departs By Stephanie Baum
BioPharma, Pharma Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug By Frank Vinluan
BioPharma, Pharma FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs By Frank Vinluan
BioPharma, Pharma Autoimmune Biotech Zenas Gets $118M to Take Antibody Drug Into Phase 3 By Frank Vinluan
BioPharma, Pharma Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma By Frank Vinluan
Health Tech, Hospitals New unicorn IntelyCare uses $115M raise to expand its data-driven nurse staffing solution By Michael Schroeder
Consumer / Employer, Health Services New unicorn on the block: Somatus hauls in $325M+ to grow its value-based kidney care model By Michael Schroeder
BioPharma, Pharma Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis By Frank Vinluan
BioPharma, Pharma Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer By Frank Vinluan
BioPharma, Pharma OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance By Frank Vinluan
